当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A new standard of care for patients with high-risk rhabdomyosarcoma? - Authors' reply.
The Lancet Oncology ( IF 41.6 ) Pub Date : 2020-01-01 , DOI: 10.1016/s1470-2045(19)30812-5
Gianni Bisogno 1 , Andrea Ferrari 2 , Soledad Gallego Melcon 3 , Gian Luca De Salvo 4 , Christophe Bergeron 5 , Meriel Jenney 6
Affiliation  

We welcome the comments of colleagues that allow us to further explain the addition of maintenance in the treatment of patients with high-risk rhabdomyosarcoma. Both letters state that the primary endpoint of our study, disease-free survival, was not satisfied. This result was thoroughly discussed in the paper, showing that disease-free survival was 77·6% with maintenance therapy and 69·8% when stopping treatment. Although this difference was not significant (p=0·061), this outcome, along with the significant improvement in overall survival, has led us to conclude that maintenance therapy should be included in treatment regimens.

中文翻译:

高危横纹肌肉瘤患者的新护理标准?-作者的答复。

我们欢迎同事的评论,这些评论使我们可以进一步解释在高危横纹肌肉瘤患者治疗中增加维持治疗的情况。两封信都指出,我们研究的主要终点(无病生存)并不令人满意。对该结果进行了详尽的讨论,表明维持治疗的无病生存率为77·6%,停止治疗时的无病生存率为69·8%。尽管这种差异不明显(p = 0·061),但这种结果以及总体生存率的显着提高使我们得出结论,维持治疗应纳入治疗方案。
更新日期:2020-01-04
down
wechat
bug